However, although most NSCLC patients who harbor TKI-sensitizing EGFR mutations show an initial pronounced response to EGFR-TKI treatment, they acquire a resistance to these drugs after ~9 to 14 months of such therapy. Here, EGFR is linked to non-small cell lung carcinoma.